1. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
- Author
-
Fan, Alice C., Deb-Basu, Debabrita, Orban, Mathias W., Gotlib, Jason R., Natkunam, Yasodha, O'Neill, Roger, Padua, Rose-Ann, Xu, Liwen, Taketa, Daryl, Shirer, Amy E., Beer, Shelly, Yee, Ada X., Voehringer, David W., and Felsher, Dean W.
- Subjects
Drug therapy ,Physiological aspects ,Genetic aspects ,Research ,Tumor proteins -- Physiological aspects -- Genetic aspects -- Research -- Drug therapy ,Cellular signal transduction -- Genetic aspects -- Research -- Physiological aspects ,Lymphomas -- Drug therapy -- Genetic aspects -- Research ,Chronic myeloid leukemia -- Genetic aspects -- Drug therapy -- Research - Abstract
Cancer is frequently associated with the abnormal expression and phosphorylation of oncogenes (1-4). Specific hematopoietic tumors are frequently characterized by the discrete activation of specific oncogenes such as MYC (5-7), [...], Current methods of protein detection are insensitive to detecting subtle changes in oncoprotein activation that underlie key cancer signaling processes. The requirement for large numbers of cells precludes serial tumor sampling for assessing a response to therapeutics. Therefore, we have developed a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes. Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin. Therefore, we have described a new and highly sensitive method for determining oncoprotein expression and phosphorylation in clinical specimens for the development of new therapeutics for cancer.
- Published
- 2009